Trials / Completed
CompletedNCT00887588
LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction
A 36-week, Randomized, Double-blind, Multi-center, Parallel Group, Active Controlled Study to Evaluate the Efficacy, Safety and Tolerability of LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 307 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The study will assess the effects of 36 weeks of treatment with LCZ696 compared to valsartan on N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) in patients with chronic heart failure and preserved left-ventricular ejection fraction.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LCZ696 | 50 mg, 100 mg and 200 mg tablets |
| DRUG | Valsartan | 40 mg, 80 mg and 160 mg tablets |
| DRUG | Placebo | matching placebo to LCZ696 and Valsartan |
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2011-12-01
- Completion
- 2011-12-01
- First posted
- 2009-04-24
- Last updated
- 2015-08-25
- Results posted
- 2015-08-13
Locations
81 sites across 14 countries: United States, Argentina, Brazil, Canada, Germany, India, Italy, Netherlands, Poland, Romania, Russia, Singapore, Spain, Venezuela
Source: ClinicalTrials.gov record NCT00887588. Inclusion in this directory is not an endorsement.